1.43
price down icon1.38%   -0.02
after-market Handel nachbörslich: 1.43
loading

Inmune Bio Inc Aktie (INMB) Neueste Nachrichten

pulisher
May 21, 2026

Inmune Bio Inc stock (US45764T1060): eyes on upcoming 2025 results and Alzheimer’s pipeline - AD HOC NEWS

May 21, 2026
pulisher
May 20, 2026

INMB Stock Price, Quote & Chart | INMUNE BIO INC (NASDAQ:INMB) - ChartMill

May 20, 2026
pulisher
May 18, 2026

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform - marketscreener.com

May 18, 2026
pulisher
May 17, 2026

Inmune Bio stock (US45764T1060): Year-end 2025 results and update in focus - AD HOC NEWS

May 17, 2026
pulisher
May 17, 2026

What INmune Bio INMB auditor changes mean for investors Q1 2026 Better Than ExpectedCommunity Pattern Alerts - Newser

May 17, 2026
pulisher
May 15, 2026

INmune Bio publishes Alzheimer’s trial results in journal - Investing.com UK

May 15, 2026
pulisher
May 15, 2026

INMB Shows Promising Alzheimer's Results in MINDFuL Trial - GuruFocus

May 15, 2026
pulisher
May 15, 2026

INmune Bio: Interview With Co-Founder & CEO David Moss About The Immunotherapies Company - Pulse 2.0

May 15, 2026
pulisher
May 15, 2026

INmune Bio publishes Alzheimer’s trial results in journal By Investing.com - Investing.com South Africa

May 15, 2026
pulisher
May 15, 2026

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform - The Manila Times

May 15, 2026
pulisher
May 15, 2026

Alzheimer’s drug XPro shows directionally consistent benefits, no ARIA - Stock Titan

May 15, 2026
pulisher
May 14, 2026

INmune Bio Receives FDA Fast Track for XPro - TipRanks

May 14, 2026
pulisher
May 14, 2026

INMB Secures Fast Track Designation for Alzheimer's Treatment - GuruFocus

May 14, 2026
pulisher
May 14, 2026

INmune Bio (NASDAQ: INMB) wins FDA Fast Track status for XPro in early Alzheimer’s disease - Stock Titan

May 14, 2026
pulisher
May 14, 2026

INmune Bio receives FDA fast track status for Alzheimer’s drug - Investing.com UK

May 14, 2026
pulisher
May 14, 2026

INmune Bio (INMB) Stock: Up +14.73%, Key Resistance at $1.76 2026-05-14Expert Entry Points - newser.com

May 14, 2026
pulisher
May 14, 2026

INmune Bio's XPro1595 gets FDA Fast Track for early Alzheimer's treatment - Pluang

May 14, 2026
pulisher
May 14, 2026

INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug By Investing.com - Investing.com South Africa

May 14, 2026
pulisher
May 14, 2026

INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug - Investing.com Australia

May 14, 2026
pulisher
May 14, 2026

INmune Bio receives FDA fast track designation for XPro1595 in early Alzheimer's disease - marketscreener.com

May 14, 2026
pulisher
May 14, 2026

INmune Bio receives FDA fast track status for Alzheimer’s drug By Investing.com - Investing.com Australia

May 14, 2026
pulisher
May 14, 2026

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease - The Manila Times

May 14, 2026
pulisher
May 14, 2026

FDA Fast Tracks brain-inflammation drug for early Alzheimer’s - Stock Titan

May 14, 2026
pulisher
May 13, 2026

INmune Bio (INMB) Q1 2026 Earnings Transcript - AOL.com

May 13, 2026
pulisher
May 11, 2026

TradingKey - TradingKey

May 11, 2026
pulisher
May 09, 2026

INmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call Transcript - Insider Monkey

May 09, 2026
pulisher
May 09, 2026

INMB: INmune BioInteractive Chart - Zacks Investment Research

May 09, 2026
pulisher
May 08, 2026

Expanding partnership aims to advance stem cell therapy to treat RDEB - Epidermolysis Bullosa News

May 08, 2026
pulisher
May 08, 2026

Q1 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus

May 08, 2026
pulisher
May 08, 2026

INmune Bio, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

May 08, 2026
pulisher
May 08, 2026

INMUNE BIO ($INMB) Releases Q1 2026 Earnings - Moomoo

May 08, 2026
pulisher
May 08, 2026

Transcript : INmune Bio Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com

May 08, 2026
pulisher
May 08, 2026

Earnings call transcript: INmune Bio Q1 2026 shows EPS beat, stock dips - Investing.com UK

May 08, 2026
pulisher
May 07, 2026

Earnings call transcript: INmune Bio Q1 2026 shows EPS beat, stock dips By Investing.com - Investing.com South Africa

May 07, 2026
pulisher
May 07, 2026

INMUNE BIO INC (NASDAQ:INMB) Beats Q1 2026 EPS Estimates as Stock Shows Recent Momentum - ChartMill

May 07, 2026
pulisher
May 07, 2026

INmune Bio (NASDAQ: INMB) posts Q1 loss and flags going concern risks - Stock Titan

May 07, 2026
pulisher
May 07, 2026

INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update - The Manila Times

May 07, 2026
pulisher
May 07, 2026

Alzheimer's drug moves toward Phase 2b/3 as CORDStrom nears UK filing - Stock Titan

May 07, 2026
pulisher
May 07, 2026

Press Release: INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update - Moomoo

May 07, 2026
pulisher
May 06, 2026

MSN Money - MSN

May 06, 2026
pulisher
May 06, 2026

INmune Bio expands collaboration with Anthony Nolan charity By Investing.com - Investing.com Australia

May 06, 2026
pulisher
May 06, 2026

INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases - The Manila Times

May 06, 2026
pulisher
May 05, 2026

INmune Bio expands collaboration with Anthony Nolan charity - Investing.com UK

May 05, 2026
pulisher
May 05, 2026

INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th - 富途牛牛

May 05, 2026
pulisher
May 05, 2026

INmune Bio Expands Cord Tissue License for CORDStrom Platform - TipRanks

May 05, 2026
pulisher
May 05, 2026

Inmune Bio And Anthony Nolan Announce Strategic Expansion - TradingView

May 05, 2026
pulisher
May 05, 2026

INmune Bio (NASDAQ: INMB) deepens Anthony Nolan CORDStrom supply pact - Stock Titan

May 05, 2026
$29.66
price down icon 0.98%
$92.25
price up icon 0.12%
$108.87
price up icon 2.48%
$53.86
price down icon 1.17%
ONC ONC
$302.44
price down icon 2.52%
$154.89
price up icon 2.20%
Kapitalisierung:     |  Volumen (24h):